DAMGO TFA (C007B-348763)

DAMGO TFA is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR.In VitroDAMGO (1-10 μM) TFA significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression. DAMGO (1 μM) TFA effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na + current (TTX-R I Na ), i.e. PGE 2 (1 μM) can increase the TTX-R I Na peak by 103 % compared to 24.9 % with the addition of DAMGO. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoDAMGO (i.v., 0.5-2 mg/kg) TFA can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid.

Specifications and Purity: ≥99%

Molecular Formula: C28H36F3N5O8

Molecular Weight: 627.61

PubChem CID: 5462471

Isomeric SMILES: C[C@H](C(=O)NCC(=O)N(C)[C@@H](CC1=CC=CC=C1)C(=O)NCCO)NC(=O)[C@H](CC2=CC=C(C=C2)O)N